Biotech and Pharma best performers w/e 10/18

Biotech was +4.8% on the week and the best performing sector, beating the wider US market by 2.5%. Biotech was the strongest industry group +6.5% on the week with Pharma lagging slightly at +4.6%. Micro cap (sub $0.8bn) Biotech was +7.7% and led sector performance.

Biotech best performers on the week:

Tevogen Bio (TVGN) +353% to $1.72 after announcing aggressive future revenue expectations for its lead drug candidate

ProQR Therapeutics (PRQR) +134% to $4.33 benefitted from the positive news from Wave Life Sciences regarding RNA editing validation which helped lift similar stocks including PRGR

Frequency Therapeutics (KRRO) +107% to $80.04 another RNA editing stock that benefited from the news at Wave Life Sciences

BioVie (BIVI) +99% to $2.35 following announcing the allowance for a Japanese patent application. The shares are -93% ytd

Wave Life Sciences (WVE) +78% to $15.31 announced that Takeda would not exercise an option on a drug candidate but concurrently provided an update on a GSK partnered drug WVE006 that suggested the drug had successfully mRNA edited in human 1b/2a trials 

Aprea Therapeutics (APRE) +69% to $4.4 on the back of stronger trading volume over the week equivalent to 4.5x annualised daily average with Wednesday and Thursday 7.8x the annualised daily average

Longboard Pharma (LBPH) +52% to $59.21 following an agreed $60 / share bid from Lundbeck

MeiraGTx (MGTX) +44% to $6.16 following a positive update on its clinical bridging study for its Parkinson's candidate 

Lexeo (LXEO) +36% to $11.12 following strong trading volumes on Friday 4.5x normal daily levels

Pharma best performers on the week:

Amylyx Pharma (AMLX) +35% to $4.78 following positive news on a Phase 2 study treating Wolfram Syndrome

Jasper Therapeutics (JSPR) +34% to $20.04 following a positive update on their 1b/2a study to treat CIndU

Eyepoint Pharma (EYPT) +25% to $11.05. The company announced an employee option grant though this in itself does not seem to explain the share price strength.

Ocular Therapeutics (OCUL) +16% to $11.33. No new news but the shares have been very strong and are +389% over 1 yr and +117% over 6 months

Indivior (INDV) +15% to $8.56. The company announced details of a share buy back of 635k shares as part of the $100m plan. The shares at -56% ytd

Harrow Health (HROW) +13% to $57.48. The shares continue to run strongly and are +130% over 3 months